Biological and clinical effects of a resveratrol-based multivitamin supplement on intracytoplasmic sperm injection cycles: a single-center, randomized controlled trial. (12th December 2022)

• Record Type: Journal Article
• Authors: Gerli, Sandro; Della Morte, Chiara; Ceccobelli, Margherita; Mariani, Monica; Favilli, Alessandro; Leonardi, Lucio; Lanti, Alessandro; Iannitti, Rossana G.; Fioretti, Bernard
• Is Part Of: Journal of maternal-fetal & neonatal medicine. Volume 35:Number 25(2022)
• Page Start: 7640
• Page End: 7648
• Publication Date: 2022-12-12
• Subjects: Resveratrol -- intracytoplasmic sperm injection -- assisted reproductive technologies -- embryo -- oocyte; Obstetrics -- Periodicals; Perinatology -- Periodicals; Infants (Newborn) -- Diseases -- Periodicals; Neonatology -- Periodicals; 618.2
• DOI: 10.1080/14767058.2021.1958313
• Languages: English
• ISSNs: 1476-7058

Abstract

Abstract: Background: Resveratrol display's positive effects on follicle growth and development in preclinical studies while there is scantly information from clinical trials. The aim of this study was to evaluate the biological and clinical impact of a resveratrol-based multivitamin supplement on intracytoplasmatic sperm injection (ICSI) cycles. Methods: A randomized, single-center controlled trial conducted at the University Center of Assisted Reproductive Technologies involving 101 women infertile women undergoing ICSI cycles was conducted. A pretreatment with a daily resveratrol based nutraceutical was administered to the Study Group; Control Group received folic acid. The primary outcomes were the number of developed mature follicles (>16 mm), total oocytes and MII oocytes recovered, the fertilization rate and the number of cleavage embryos/blastocysts obtained. Secondary endpoints were the duration and dosage of gonadotropins, the number of embryos for transfer, implantation, biochemical, clinical pregnancy rates, live birth and miscarriage rates. Results: A significantly higher number of oocytes and MII oocytes were retrieved in the Study Group than in Control Group ( p = .03 and p = .04, respectively). A higher fertilization rate ( p = .004), more cleavage embryos/patient ( p = .01), blastocytes/patients ( p = .01) and cryopreserved embryos ( p = .03) were obtained in the Study Group. No significant differences in biochemical or clinical pregnancy, live birth, and miscarriage rates were revealed, but a trend to a higher live birth rate was revealed in the Study Group. Conclusions: A 3 months period of dietary supplementation with a resveratrol-based multivitamin nutraceutical leads to better biological effects on ICSI cycles. Trial registration number: ClinicalTrials.gov registration identifier: NCT04386499